tella, Inc. Tella, Inc. is specialized in the research and development of dendritic cell (DC) vaccine therapy, which is one type of cancer vaccine, and offers technologies and know-how to medical institutions that include university hospitals and national hospitals. DC vaccine therapy is a novel treatment method that enhances the function of the patient's own immune cells and allows DCs to attack the cancer selectively. Securities Code 2191 Industrial Classification Services Stock Market JASDAQ URL English : http://www.tella.jp/en/ Japanese : http://www.tella.jp/ News Release 11/15/2011 Notice Regarding Issuance of New Shares by way of Third-party Allotment  (43KB) 11/07/2011 Collaborative Clinical Study for Advanced Melanoma Starts with Keio University School of Medicine  (15KB) 11/07/2011 Collaborative Clinical Study for Advanced and Recurrent Esophageal Cancer Starts with Keio University School of Medicine  (16KB) 10/12/2011 tella Signs Joint Research Agreement with the National Center for Global Health and Medicine  (17KB) 09/30/2011 Joint R&D with Asahi Kasei for Cell Processing Equipment for Cancer Treatment  (17KB) Financial Data 11/04/2011 Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending December 31, 2011(Nine months ended September 30, 2011)  (87KB) 08/04/2011 Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending December 31, 2011(Six months ended June 30, 2011)  (85KB) 05/10/2011 Consolidated Financial Results for the First Quarter of the Fiscal Year Ending December 31, 2011(Three months ended March 31, 2011)  (74KB) 02/10/2011 Non-consolidated Financial Results for the Fiscal Year Ended December 31, 2010  (198KB) Copyright(C)2002-2012 ACE CONSULTING CO., LTD.